Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

被引:467
作者
Simek, Melissa D. [1 ]
Rida, Wasima
Priddy, Frances H. [1 ]
Pung, Pham [2 ]
Carrow, Emily [10 ]
Laufer, Dagna S. [1 ]
Lehrman, Jennifer K. [1 ]
Boaz, Mark [1 ]
Tarragona-Fiol, Tony [17 ]
Miiro, George [6 ]
Birungi, Josephine [7 ]
Pozniak, Anton [9 ]
McPhee, Dale A. [8 ]
Manigart, Olivier [5 ]
Karita, Etienne [5 ]
Inwoley, Andre [11 ]
Jaoko, Walter [12 ]
DeHovitz, Jack [13 ]
Bekker, Linda-Gail [14 ]
Pitisuttithum, Punnee [15 ]
Paris, Robert [16 ]
Walker, Laura M. [3 ,4 ]
Poignard, Pascal [3 ,4 ]
Wrin, Terri [2 ]
Fast, Patricia E. [1 ]
Burton, Dennis R. [3 ,4 ]
Koff, Wayne C. [1 ]
机构
[1] Int AIDS Vaccine Initiat, New York, NY 10028 USA
[2] Monogram Biosci Inc, San Francisco, CA USA
[3] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA
[4] Scripps Res Inst, Int AIDS Vaccine Initiat, Neutralizing Antibody Ctr, La Jolla, CA 92037 USA
[5] Emory Univ, Rwanda Zambia HIV Res Grp, Atlanta, GA 30322 USA
[6] MRC, Uganda Virus Res Inst, Entebbe, Uganda
[7] Int AIDS Vaccine Initiat, Uganda Virus Res Inst, Entebbe, Uganda
[8] Natl Ctr HIV1 Epidemiol & Clin Res, Natl Serol Reference Lab, Fitzroy, Vic, Australia
[9] St Stephens AIDS Trust, London, England
[10] Adv BioAdjuvants LLC, Omaha, NE USA
[11] CeDReS, Diagnost Ctr & Res AIDS & Opportunist dis, Abidjan, Cote Ivoire
[12] Univ Nairobi, Kenya AIDS Vaccine Initiat, Nairobi, Kenya
[13] Suny Downstate Med Ctr, Dept Prevent Med, Brooklyn, NY 11203 USA
[14] Univ Cape Town, Desmond Tutu HIV1 Fdn, ZA-7925 Cape Town, South Africa
[15] Mahidol Univ, Dept Clin Trop Med, Clin Infect Dis Res Unit, Vaccine Trial Ctr, Bangkok 10700, Thailand
[16] Mahidol Univ, Dept Retrovirol, Armed Forces Res Inst Med Sci, Bangkok 10700, Thailand
[17] Univ London Imperial Coll Sci Technol & Med, IAVI Core Lab, London, England
关键词
HUMAN MONOCLONAL-ANTIBODIES; CROSS-CLADE NEUTRALIZATION; INFECTIOUS-DISEASES; H5N1; VACCINE; HIV-1; GP120; COMBINATORIAL LIBRARIES; PASSIVE-IMMUNIZATION; CLINICAL-TRIAL; CHALLENGE; RESPONSES;
D O I
10.1128/JVI.00110-09
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The development of a rapid and efficient system to identify human immunodeficiency virus type 1 (HIV-1)infected individuals with broad and potent HIV-1-specific neutralizing antibody responses is an important step toward the discovery of critical neutralization targets for rational AIDS vaccine design. In this study, samples from HIV-1-infected volunteers from diverse epidemiological regions were screened for neutralization responses using pseudovirus panels composed of clades A, B, C, and D and circulating recombinant forms (CRFs). Initially, 463 serum and plasma samples from Australia, Rwanda, Uganda, the United Kingdom, and Zambia were screened to explore neutralization patterns and selection ranking algorithms. Samples were identified that neutralized representative isolates from at least four clade/CRF groups with titers above prespecified thresholds and ranked based on a weighted average of their log-transformed neutralization titers. Linear regression methods selected a five-pseudovirus subset, representing clades A, B, and C and one CRF01_AE, that could identify top-ranking samples with 50% inhibitory concentration (IC(50)) neutralization titers of >= 100 to multiple isolates within at least four clade groups. This reduced panel was then used to screen 1,234 new samples from the Ivory Coast, Kenya, South Africa, Thailand, and the United States, and 1% were identified as elite neutralizers. Elite activity is defined as the ability to neutralize, on average, more than one pseudovirus at an IC(50) titer of 300 within a clade group and across at least four clade groups. These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design.
引用
收藏
页码:7337 / 7348
页数:12
相关论文
共 55 条
  • [1] Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    Binley, JA
    Wrin, T
    Korber, B
    Zwick, MB
    Wang, M
    Chappey, C
    Stiegler, G
    Kunert, R
    Zolla-Pazner, S
    Katinger, H
    Petropoulos, CJ
    Burton, DR
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (23) : 13232 - 13252
  • [2] Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C
    Binley, James M.
    Lybarger, Elizabeth A.
    Crooks, Emma T.
    Seaman, Michael S.
    Gray, Elin
    Davis, Katie L.
    Decker, Julie M.
    Wycuff, Diane
    Harris, Linda
    Hawkins, Natalie
    Wood, Blake
    Nathe, Cory
    Richman, Douglas
    Tomaras, Georgia D.
    Bibollet-Ruche, Frederic
    Robinson, James E.
    Morris, Lynn
    Shaw, George M.
    Montefiori, David C.
    Mascola, John R.
    [J]. JOURNAL OF VIROLOGY, 2008, 82 (23) : 11651 - 11668
  • [3] EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY
    BURTON, DR
    PYATI, J
    KODURI, R
    SHARP, SJ
    THORNTON, GB
    PARREN, PWHI
    SAWYER, LSW
    HENDRY, RM
    DUNLOP, N
    NARA, PL
    LAMACCHIA, M
    GARRATTY, E
    STIEHM, ER
    BRYSON, YJ
    CAO, YZ
    MOORE, JP
    HO, DD
    BARBAS, CF
    [J]. SCIENCE, 1994, 266 (5187) : 1024 - 1027
  • [4] HUMAN-ANTIBODIES FROM COMBINATORIAL LIBRARIES
    BURTON, DR
    BARBAS, CF
    [J]. ADVANCES IN IMMUNOLOGY, VOL 57, 1994, 57 : 191 - 280
  • [5] A LARGE ARRAY OF HUMAN MONOCLONAL-ANTIBODIES TO TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS FROM COMBINATORIAL LIBRARIES OF ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS
    BURTON, DR
    BARBAS, CF
    PERSSON, MAA
    KOENIG, S
    CHANOCK, RM
    LERNER, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) : 10134 - 10137
  • [6] HIV vaccine design and the neutralizing antibody problem
    Burton, DR
    Desrosiers, RC
    Doms, RW
    Koff, WC
    Kwong, PD
    Moore, JP
    Nabel, GJ
    Sodroski, J
    Wilson, IA
    Wyatt, RT
    [J]. NATURE IMMUNOLOGY, 2004, 5 (03) : 233 - 236
  • [7] An AIDS vaccine: no time to give up
    Burton, DR
    Desrosiers, RC
    Johnson, PR
    Koff, WC
    [J]. LANCET, 2004, 364 (9449) : 1938 - 1938
  • [8] A vaccine for HIV type 1: The antibody perspective
    Burton, DR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) : 10018 - 10023
  • [9] NEUTRALIZATION OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES BY THE BROADLY REACTIVE ANTI-V3 MONOCLONAL-ANTIBODY, 447-52D
    CONLEY, AJ
    GORNY, MK
    KESSLER, JA
    BOOTS, LJ
    OSSORIOCASTRO, M
    KOENIG, S
    LINEBERGER, DW
    EMINI, EA
    WILLIAMS, C
    ZOLLAPAZNER, S
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (11) : 6994 - 7000
  • [10] Serologic response to inactivated poliovirus vaccine:: A randomized clinical trial comparing 2 vaccination schedules in Puerto Rico
    Dayan, Gustavo H.
    Thorley, Margaret
    Yamamura, Yasuhiro
    Rodriguez, Nayra
    McLaughlin, Steve
    Torres, Lourdes M.
    Seda, Antonio
    Carbia, Marcia
    Alexander, Lorraine N.
    Caceres, Victor
    Pallansch, Mark A.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (01) : 12 - 20